Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$759.00K$759.00Kno prior Q3 2022 on file Net Income-$24.02M-$24.02Mno prior Q3 2022 on file EPS Diluted-$0.39-$0.39no prior Q3 2022 on file Operating Income-$27,440,000— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$22,971,000— Margins · derivedOperating margin-3615.3%
Net margin-3164.3%
ended Sep 30, 2023 · filed Nov 7, 2023 · 38 d after period end